Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG814

—

db211c23-0e18-50a8-b592-2624f89e8023

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.630
  • INTERFERON_GAMMA_RESPONSE+0.630
  • INTERFERON_ALPHA_RESPONSE+0.623
  • IL6_JAK_STAT3_SIGNALING+0.614
  • INFLAMMATORY_RESPONSE+0.518
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.491
  • COMPLEMENT+0.468
  • IL2_STAT5_SIGNALING+0.324
  • KRAS_SIGNALING_UP+0.314
  • UNFOLDED_PROTEIN_RESPONSE+0.264

Top 10 suppressed

  • NOTCH_SIGNALING-0.256
  • CHOLESTEROL_HOMEOSTASIS-0.235
  • TGF_BETA_SIGNALING-0.211
  • OXIDATIVE_PHOSPHORYLATION-0.205
  • ESTROGEN_RESPONSE_EARLY-0.129
  • KRAS_SIGNALING_DN-0.106
  • HEDGEHOG_SIGNALING-0.105
  • MYC_TARGETS_V1-0.096
  • ESTROGEN_RESPONSE_LATE-0.094
  • HEME_METABOLISM-0.068

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG539
mng-umap@100
——0.880
2MNG751
mng-umap@100
——0.870
3MNG256
mng-umap@100
——0.865
4C3N-00247
lung-landscapes@6
—cohortMD20.861
5BSR_08_0248_H3_S58
breast-umap@18
—D0.856
6SRR1516052
bladder-landscape@3
——0.847
720130243.TNBC
breast-umap@18
—D0.841
8SRR8518252
breast-umap@18
—A0.838
9s0112287
melanoma-umap@29
——0.835
10346fe4c0-2ea0-45b4-8863-b0f9e7756ad6
melanoma-umap@29
——0.834

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.630Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.630Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.623Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.614Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.518Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.491Inavolisib— uncovered
COMPLEMENT0.468Inavolisib— uncovered
IL2_STAT5_SIGNALING0.324Idelalisib— uncovered
KRAS_SIGNALING_UP0.314Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.264Idelalisib— uncovered
ANGIOGENESIS0.256Remibrutinib— uncovered
G2M_CHECKPOINT0.253Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.253Inavolisib— uncovered
COAGULATION0.241Binimetinib— uncovered
MITOTIC_SPINDLE0.236Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.211Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.190Inavolisib— uncovered
E2F_TARGETS0.188Inavolisib— uncovered
P53_PATHWAY0.187Idelalisib— uncovered
APOPTOSIS0.184Idelalisib— uncovered